An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
For people with relapsed or refractory diffuse large B-cell lymphoma
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
Subscribe To Our Newsletter & Stay Updated
